Evidence map›Paper›PMID 38903711›Full record

ReviewFrontiers in oncology2024

Progress in the study of antibody-drug conjugates for the treatment of cervical cancer.

Congcong Zhai, Yan Cui, Ling Guo, Cixiang Chen, Yanfang Song, Jinghua Zhong, Yili Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Congcong ZhaiDepartment of Oncology, Gannan Medical University, Ganzhou, China.
Yan CuiDepartment of Oncology, Bengbu Medical University, Lu'an, China.
Ling GuoDepartment of Oncology, Gannan Medical University, Ganzhou, China.
Cixiang ChenDepartment of Oncology, Gannan Medical University, Ganzhou, China.
Yanfang SongDepartment of Oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Jinghua ZhongDepartment of Oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Yili WangDepartment of Oncology, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is the second most prevalent malignancy affecting women's health globally, and the number of morbidity and mortality from cervical cancer continues to rise worldwide. The 5-year survival rate of patients with recurrent or metastatic cervical cancer is significantly reduced, and existing treatment modalities have low efficacy and high adverse effects, so there is a strong need for new, effective, and well-tolerated therapies. Antibody-drug conjugates (ADCs) are a new targeted therapeutic modality that can efficiently kill tumor cells. This review aims to summarize the composition, research, and development history and mechanism of action of ADCs, to review the research progress of ADCs in the treatment of cervical cancer, and to summarize and prospect the application of ADCs.

Indexed as

antibody-drug conjugatescervical cancerclinical researchdrug developmenttargeted therapy

Identifiers

PMID38903711
PMCPMC11187480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.